TrialThe lancet. Gastroenterology & hepatology2022

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.

Thomas U Marron et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.